Press Releases

    • AUG 11 2017

    ONC201 Trial for Neuroendocrine Cancer Begins at Cleveland Clinic

    Philadelphia, PA (Aug 9, 2017) – Oncoceutics, Inc. announced today that the first patient has been treated in a Phase II clinical trial of ONC201 for patients with recurrent or metastatic neuroendocrine tumors at the Cleveland Clinic. The selection of neuroendocrine tumors for a clinical trial was driven by the discovery in 2016 that ONC201

    • JUL 10 2017

    Mechanistic Study Uncovers New Utility of ONC201 Mechanism in Lymphoma

    Philadelphia, PA (July 10, 2017) – Oncoceutics, Inc. announced the publication of a scientific manuscript from collaborators at the University of Texas MD Anderson Cancer Center (MDACC) that describes ONC201’s ability to control a set of anti-cancer signaling pathways to induce cell death in tumor, but not  normal cells. The publication, from the laboratory of

    • JUN 28 2017

    Oncoceutics Extends Patent Family to Include ONC201 in Leukemias

    Philadelphia, PA (June 28, 2017) – Oncoceutics, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued patent #9,688,679 for the use of ONC201 to treat all leukemias, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). ONC201, a member of the imipridone family, has demonstrated anti-cancer activity and safety in preclinical

    • MAY 30 2017

    Efficacy Results for ONC201 in Recurrent Glioblastoma Published

    Philadelphia, PA (May 30, 2017) – Oncoceutics, Inc. announced that results from the first cohort of the Phase II trial for patients with recurrent glioblastoma treated with the company’s lead imipridone, ONC201, were recently published in the journal Oncotarget. The study, conducted at Massachusetts General Hospital (MGH) and the Dana Farber Cancer Institute (DFCI), demonstrated